Individually Targeted Human Milk Fortification

IF 17.1 1区 医学 Q1 PEDIATRICS
Mandy Brown Belfort, Banu Ahtam, Katherine A. Bell, Paige Berger, Sara Cherkerzian, Deirdre Ellard, Laurie Foster, Christoph Fusch, Borjan Gagoski, P. Ellen Grant, Manasa Kuncham, Hunter Pepin, Marina Solti, Tina Steele, Lianne Woodward, Terrie Inder
{"title":"Individually Targeted Human Milk Fortification","authors":"Mandy Brown Belfort, Banu Ahtam, Katherine A. Bell, Paige Berger, Sara Cherkerzian, Deirdre Ellard, Laurie Foster, Christoph Fusch, Borjan Gagoski, P. Ellen Grant, Manasa Kuncham, Hunter Pepin, Marina Solti, Tina Steele, Lianne Woodward, Terrie Inder","doi":"10.1001/jamapediatrics.2026.4220","DOIUrl":null,"url":null,"abstract":"Importance Human milk is recommended for hospitalized very preterm infants, but the optimal macronutrient fortification strategy is unknown. Objective To compare individually targeted fortification using point-of-care human milk analysis with standard-of-care fortification. Design, Setting, and Participants This double-blind randomized clinical trial enrolled participants from February 2020 to March 2025 at a single academic level III neonatal intensive care unit (NICU), with outcomes assessed through NICU discharge. Very preterm infants born at 24 to 30 completed weeks’ gestation were eligible for inclusion. Data were analyzed from June 2025 to March 2026. Intervention All participants received standard of care comprising maternal and/or pasteurized donor human milk (termed <jats:italic>base milk</jats:italic> ) fortified with commercial multicomponent human milk fortifier and protein modular, with additional protein and/or fat provided for clinical growth faltering. The intervention group received protein and/or fat beyond standard of care when indicated by milk analysis with midinfrared spectroscopy (Miris Human Milk Analyzer [HMA] version 08-2-02-107 [Miris AB]), targeting minimum true protein of 1 g/dL and energy of 67 kcal/dL in base milk. Main Outcomes and Measures Primary outcomes were <jats:italic>z</jats:italic> scores of body weight and length at study diet end; fat-free mass measured with air displacement plethysmography; and quantitative metrics from brain magnetic resonance imaging (MRI) near term-equivalent age. Results Of 251 eligible infants, 206 were approached and 130 consented, were randomized, and received the study diet (65 each in the control and intervention groups); 113 infants (87%) completed the study diet though 36 weeks’ postmenstrual age. Mean (SD) gestational age was 28.5 (1.9) weeks, and mean (SD) birth weight was 1165 (298) g. Median (IQR) true protein content of base milk (control: 1.24 [1.13-1.34] g/dL vs intervention: 1.18 [1.12-1.32] g/dL) and total protein intake from base milk and all fortifiers (control: 4.58 [4.44-4.74] g/kg/d vs intervention: 4.47 [4.31-4.60] g/kg/d) were unexpectedly higher in the control group; fat and energy content and intakes were similar between groups. Nutrient intakes all met or exceeded recommended levels in both groups. In intention-to-treat analyses, there was no evidence that <jats:italic>z</jats:italic> scores of weight, length, and head circumference, body composition, or brain MRI indices differed between groups. Results were similar in analyses limited to infants who completed the study diet. Conclusions and Relevance Findings in this randomized clinical trial do not support routine use of point-of-care human milk analysis to inform individually targeted human milk fortification in the NICU. Trial Registration ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"https://clinicaltrials.gov/study/NCT03977259?cond=NCT03977259&amp;amp;amp;viewType=Card&amp;amp;amp;rank=1\">NCT03977259</jats:ext-link>","PeriodicalId":14683,"journal":{"name":"JAMA Pediatrics","volume":"33 1","pages":""},"PeriodicalIF":17.1000,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamapediatrics.2026.4220","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

Importance Human milk is recommended for hospitalized very preterm infants, but the optimal macronutrient fortification strategy is unknown. Objective To compare individually targeted fortification using point-of-care human milk analysis with standard-of-care fortification. Design, Setting, and Participants This double-blind randomized clinical trial enrolled participants from February 2020 to March 2025 at a single academic level III neonatal intensive care unit (NICU), with outcomes assessed through NICU discharge. Very preterm infants born at 24 to 30 completed weeks’ gestation were eligible for inclusion. Data were analyzed from June 2025 to March 2026. Intervention All participants received standard of care comprising maternal and/or pasteurized donor human milk (termed base milk ) fortified with commercial multicomponent human milk fortifier and protein modular, with additional protein and/or fat provided for clinical growth faltering. The intervention group received protein and/or fat beyond standard of care when indicated by milk analysis with midinfrared spectroscopy (Miris Human Milk Analyzer [HMA] version 08-2-02-107 [Miris AB]), targeting minimum true protein of 1 g/dL and energy of 67 kcal/dL in base milk. Main Outcomes and Measures Primary outcomes were z scores of body weight and length at study diet end; fat-free mass measured with air displacement plethysmography; and quantitative metrics from brain magnetic resonance imaging (MRI) near term-equivalent age. Results Of 251 eligible infants, 206 were approached and 130 consented, were randomized, and received the study diet (65 each in the control and intervention groups); 113 infants (87%) completed the study diet though 36 weeks’ postmenstrual age. Mean (SD) gestational age was 28.5 (1.9) weeks, and mean (SD) birth weight was 1165 (298) g. Median (IQR) true protein content of base milk (control: 1.24 [1.13-1.34] g/dL vs intervention: 1.18 [1.12-1.32] g/dL) and total protein intake from base milk and all fortifiers (control: 4.58 [4.44-4.74] g/kg/d vs intervention: 4.47 [4.31-4.60] g/kg/d) were unexpectedly higher in the control group; fat and energy content and intakes were similar between groups. Nutrient intakes all met or exceeded recommended levels in both groups. In intention-to-treat analyses, there was no evidence that z scores of weight, length, and head circumference, body composition, or brain MRI indices differed between groups. Results were similar in analyses limited to infants who completed the study diet. Conclusions and Relevance Findings in this randomized clinical trial do not support routine use of point-of-care human milk analysis to inform individually targeted human milk fortification in the NICU. Trial Registration ClinicalTrials.gov Identifier: NCT03977259
针对个人的母乳强化
母乳被推荐用于住院的极早产儿,但最佳的常量营养素强化策略尚不清楚。目的比较护理点母乳分析与标准护理强化的个体化针对性。设计、环境和参与者本双盲随机临床试验于2020年2月至2025年3月在单个III级新生儿重症监护病房(NICU)招募参与者,通过NICU出院评估结果。在妊娠24至30周出生的极早产儿符合纳入条件。数据分析时间为2025年6月至2026年3月。所有参与者都接受了标准护理,包括母体和/或巴氏消毒的供体母乳(称为基础奶),强化了商业多组分母乳强化剂和蛋白质模块,并提供了额外的蛋白质和/或脂肪,用于临床生长迟缓。干预组使用中红外光谱(Miris Human milk Analyzer [HMA] version 08-2-02-107 [Miris AB])进行牛奶分析时,给予超过标准护理的蛋白质和/或脂肪,目标是基础奶中最低真蛋白质为1克/分升,能量为67千卡/分升。主要结局和测量主要结局为研究饮食结束时体重和身高的z分;用空气置换体积描记仪测量无脂质量;以及来自脑磁共振成像(MRI)的近期等效年龄的定量指标。结果在251名符合条件的婴儿中,206名被接近,130名同意,随机分组,接受研究饮食(对照组和干预组各65名);113名婴儿(87%)在经后36周完成了研究饮食。平均(SD)胎龄为28.5(1.9)周,平均(SD)出生体重为1165 (298)g。对照组基础乳真蛋白质含量中位数(IQR)(对照组:1.24 [1.13-1.34]g/dL,干预组:1.18 [1.12-1.32]g/dL),对照组基础乳和所有强化剂的总蛋白质摄入量(对照组:4.58 [4.44-4.74]g/kg/d,干预组:4.47 [4.31-4.60]g/kg/d)出乎意料地更高;两组之间的脂肪和能量含量及摄入量相似。两组的营养摄入量均达到或超过了推荐水平。在意向治疗分析中,没有证据表明体重、长度、头围、身体成分或脑MRI指数的z分数在两组之间存在差异。对完成研究饮食的婴儿的分析结果相似。结论和相关性本随机临床试验的结果不支持在新生儿重症监护室常规使用即时人乳分析来为个体针对性地强化人乳提供信息。试验注册ClinicalTrials.gov标识符:NCT03977259
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JAMA Pediatrics
JAMA Pediatrics PEDIATRICS-
CiteScore
31.60
自引率
1.90%
发文量
357
期刊介绍: JAMA Pediatrics, the oldest continuously published pediatric journal in the US since 1911, is an international peer-reviewed publication and a part of the JAMA Network. Published weekly online and in 12 issues annually, it garners over 8.4 million article views and downloads yearly. All research articles become freely accessible online after 12 months without any author fees, and through the WHO's HINARI program, the online version is accessible to institutions in developing countries. With a focus on advancing the health of infants, children, and adolescents, JAMA Pediatrics serves as a platform for discussing crucial issues and policies in child and adolescent health care. Leveraging the latest technology, it ensures timely access to information for its readers worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书